HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

4,4-difluororetinoic acid

RN given refers to cpd without isomeric designation

Also Known As:

4,4-difluororetinoic acid, (13-cis)-isomer; DFRA

Networked: 8 relevant articles (0 outcomes, 2 trials/studies)

Bio-Agent Context: Research Results

Experts

1.	Ambrose, Stephanie J: 1 article (10/2021)
2.	Hall, Ruth M: 1 article (10/2021)
3.	Bekiari, Eleni: 1 article (01/2013)
4.	Mainou, Maria: 1 article (01/2013)
5.	Tsapas, Apostolos: 1 article (01/2013)
6.	Vetsiou, Evaggelia: 1 article (01/2013)
7.	Vlachaki, Efthymia: 1 article (01/2013)
8.	Karakukcu, Cigdem: 1 article (01/2012)
9.	Karakukcu, Musa: 1 article (01/2012)
10.	Ozdemir, Mehmet A: 1 article (01/2012)

Related Diseases

1.	Thalassemia 01/01/2012 - "The study included 44 β-TM patients undergoing deferasirox (DFRA) or deferoxamine (DFO) chelation monotherapies or combined therapy with deferiprone (L1) and DFO, 20 patients with β-thalassemia (β-thal) traits and a control group of 22 healthy sex- and age-matched subjects. "
2.	Sickle Cell Anemia (Hemoglobin S Disease) 01/01/2013 - "These results are in accordance with previous studies about the use of DFRA in sickle cell disease." 01/01/2013 - "The aim of this report is to present the preliminary results of a pilot study assessing the effect of 4 years of DFRA treatment in six patients with sickle cell disease who are in need of recurrent transfusions. "
3.	Iron Overload 05/01/2011 - "A 18.75-year-old male with β-thalassemia major received oral DFRA therapy due to transfusional iron overload for 27 months. " 01/01/2013 - "Deferasirox (DFRA) is a novel oral chelator agent for treatment of iron overload. " 01/01/2011 - "Administration of L1 in a daily dose of at least 75 mg/kg may represent an alternative approach in treatment of mild and moderate iron overload in MDS patients who cannot be treated with deferasirox (DFRA) or deferoxamine (DFO)."
4.	Hypophosphatemia 05/01/2011 - "After we discontinued DFRA, he recovered fully without hepatic dysfunction, thrombocytopenia, proteinuria, glucosuria, and hypophosphatemia. "
5.	Liver Failure 01/01/2008 - "Cases of fatal, acute, irreversible renal and liver failure, fatal agranulocytosis and other toxicities have recently been reported with DFRA. "

Related Drugs and Biologics

1.	Deferasirox
2.	Deferoxamine (Desferal)
3.	Deferiprone
4.	Chelating Agents
5.	Iron
6.	Ferritins (Ferritin)

Related Therapies and Procedures

1.	Therapeutics